Siliq (brodalumab) / AstraZeneca, Bausch Health, LEO Pharma, Kyowa Kirin - LARVOL DELTA

Predictive Factors of Eczematous Eruptions and Candidiasis during anti IL-17 Treatment in Psoriatic Patients: a Multicenter Italian Real-life Experience in Lazio Region. (PubMed, Clin Exp Dermatol) - "Anti-IL-17 therapies show varying risks of eczema and candidiasis. Personalized strategies, regular monitoring, and prophylactic measures are essential to improve outcomes."

Biomarker • Journal • Atopic Dermatitis • Candidiasis • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. (PubMed, Acta Derm Venereol) - "Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data...Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab...The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy."

Clinical • Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A

IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies. (PubMed, Expert Rev Clin Immunol) - "In this review article, we have outlined the primary evidence regarding the biological functions of IL-17A in PsA, and summarized data from randomized controlled trials (RCTs) on PsA and psoriasis approved secukinumab, ixekizumab, bimekizumab, brodalumab, and emerging IL-17 inhibitors. Brodalumab, which inhibits the IL-17 receptor A (IL-17RA), represent an efficacious strategy for psoriasis.Continued research into the role of IL-17s in PsA pathogenesis is crucial for improving our understanding of the disease and developing more effective therapeutic strategies. Further research and advancements in biologic therapies will refine IL-17 inhibitory strategies, potentially improving outcomes for PsA patients, and other immune-mediated diseases."

Journal • Review • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL17RA

Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis. (PubMed, Front Immunol) - "This systematic review and meta-analysis aims to evaluate the risk of new-onset IBD in psoriasis patients treated with five interleukin inhibitors (Bimekizumab, Ixekizumab, Secukinumab, Brodalumab, and Ustekinumab), providing insights to inform clinical decision-making. Additionally, compared to the control group, no significant difference was observed in the risk of diarrhea as an adverse event among patients treated with Bimekizumab, Secukinumab, and Brodalumab. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024608423, identifier CRD42024608423."

Clinical • Journal • Retrospective data • Review • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis

Safety & Persistence of Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: 6-Month Follow-up Interim Results from the CARE Study (CDA 2025) - "Brodalumab showed high treatment persistence and was well tolerated during the 6-month follow-up period."

Clinical • Real-world • Real-world evidence • Cardiovascular • Dermatology • Diabetes • Hypertension • Immunology • Inflammatory Arthritis • Metabolic Disorders • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Type 2 Diabetes Mellitus

Real-World Effectiveness of Brodalumab in Canadian Patients with Plaque Psoriasis: CARE Study 6-Month Interim Data (CDA 2025) - "Improvements in the signs and symptoms of psoriasis were observed after 3 months of brodalumab therapy and were maintained or further improved after 6 months."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Psoriasis

Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice. (PubMed, Actas Dermosifiliogr) - "This study identified genetic variations associated with the ability to achieve an optimal response to brodalumab, providing potential insights into its efficacy profile for treating plaque psoriasis."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • HTR2A

SOCIAL MEDIA PERSPECTIVES OF BIOLOGICS AND TARGETED THERAPY IN PSORIATIC ARTHRITIS (EULAR 2025) - "We then narrowed the search to specific treatments using the term ‘psoriatic arthritis’ coupled with ‘adalimumab’, ‘baricitinib’ ‘brodalumab’, ‘certolizumab’, ‘etanercept’, ‘guselkumab’, ‘infliximab’, ‘ixekizumab’, ‘risankizumab’, ‘secukinumab’, ‘tildrakizumab’, ‘tofacitinib’, ‘upadacitinib’, and ‘ustekinumab’ and as well as their respective brand names. Social media perceptions of biologics and targeted therapies are largely positive, however there is significant commentary on downsides including local/systemic adverse effects and lack/loss of efficacy. It is important that physicians in their consultations address these common patient concerns that may be perpetuated by social media."

Immunology • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Dose modulation strategies in psoriatic patients: real-world comparison between secukinumab and brodalumab for up to one year after dose spacing. (PubMed, Clin Exp Dermatol) - "Therapeutic modulation of IL-17 inhibitors in patients with psoriasis and controlled disease seems an effective therapeutic strategy that maintains efficacy for up to one year in 40% of patients. No differences were observed between secukinumab and brodalumab during the D-S regimen."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A

Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study. (PubMed, J Dermatolog Treat) - "Regaining disease control and reducing physical impairment achieved highest PBI-scores. LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits - irrespective of their disease severity."

HEOR • Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A • IL17RA

Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple Sclerosis-like syndrome: a systematic review. (PubMed, Rheumatol Int) - No abstract available

Journal • Review • Ankylosing Spondylitis • CNS Disorders • Dermatology • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Multiple Sclerosis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab. (PubMed, Dermatol Reports) - "Rapid and complete remission of both pustular and plaque psoriasis was achieved and maintained for over 60 weeks. This case supports the efficacy of IL-17 pathway blockade in managing paradoxical GPP and highlights the importance of prompt recognition and appropriate therapeutic switching in severe biologic-induced psoriasis."

Journal • Dermatology • Immunology • Psoriasis • Pustular Psoriasis • IL17A • IL17RA

DMARDs and biologics are protective against alopecia areata in psoriasis patients (SID 2025) - "DMARDs analyzed included methotrexate, cyclosporine, apremilast. Biologic therapies included TNF-alpha inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab), IL-17 inhibitors (brodalumab, ixekizumab, secukinumab, bimekizumab), and IL-12/23 and IL-23 inhibitors (ustekinumab, guselkumab, risankizumab, tildrakizumab)...IL-17 inhibitors (n=7, 670) were associated with a non-significant decrease in risk (RR: 0.909; 95% CI: 0.386-2.138). These findings demonstrate the protective nature of DMARDS and biologics, particularly TNF-alpha, IL-12/23, and IL-23 inhibitors, against AA in PsO patients, highlighting the need for further research into shared mechanisms of disease underlying PsO and AA."

Clinical • Alopecia • Dermatology • Genetic Disorders • Immunology • Inflammation • Obesity • Psoriasis • IL12A • IL17A • IL23A

Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors. (PubMed, Inflammopharmacology) - "This systematic review highlights the enhanced efficacy of IL-17 and IL-23 inhibitors compared to TNF-α inhibitors, with IL-23-targeting agents demonstrating superior long-term disease control. Small molecule inhibitors, particularly Deucravacitinib, present a promising alternative as effective oral therapies. Although newer biologics offer improved treatment outcomes, further head-to-head trials comparing TYK2, JAK, and PDE4 inhibitors with IL-17 and IL-23 agents are warranted. These findings provide valuable insights to inform clinical decision-making and optimise Psoriasis management strategies."

Journal • Review • Candidiasis • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A • IL23A • TYK2

Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Immunology • IL17A

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study. (PubMed, J Eur Acad Dermatol Venereol) - "Guselkumab and risankizumab have the most favourable drug survival for effectiveness, with comparable safety to ustekinumab, and more favourable than other BADBIR biologics. Longer drug survival may reduce treatment burden by minimizing treatment switches, clinic visits and disease flares, supporting IL-23p19 inhibitors as a practical long-term option for psoriasis."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • IL23A

Analysis and mining of brodalumab adverse events based on FAERS database. (PubMed, Sci Rep) - "This study evaluated the real-world safety profile of brodalumab and identified several unexpected AEs, such as palmoplantar pustulosis and extranodal marginal zone b-cell lymphoma (malt type). These findings provide new safety insights for clinicians and may contribute to the safer and more rational use of brodalumab in clinical practice."

Adverse events • Journal • B Cell Lymphoma • Dermatology • Extranodal Marginal Zone Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis

Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System (ISPOR 2025) - "Deucravacitinib presented the lowest cost-per-response ratio amongst all treatments available for moderate to severe plaque psoriasis in the Brazilian private"

Dermatology • Immunology • Inflammation • Psoriasis

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry. (PubMed, J Eur Acad Dermatol Venereol) - "Our data support that, overall, the new biologic treatments have a superior safety profile in real-world practice compared to adalimumab and its biosimilars."

Adverse events • Journal • Dermatology • Immunology • Oncology • Psoriasis

Successful treatment of localized scleroderma using brodalumab: A case report. (PubMed, SAGE Open Med Case Rep) - "We report the first documented use of brodalumab, an IL-17 receptor antagonist, for treating severe linear localized scleroderma refractory to conventional therapies, including methotrexate, mycophenolate mofetil and corticosteroids. The patient demonstrated rapid and sustained improvement in disease activity and severity, highlighting the potential role of IL-17 signaling in the pathogenesis of localized scleroderma. This case supports further investigation of IL-17 pathway blockade in autoimmune fibrotic diseases."

Journal • Fibrosis • Immunology • Oncology • Scleroderma • Systemic Sclerosis • IL17A • IL17RA

Brodalumab in the Treatment of Immune-Related Adverse Events (clinicaltrials.gov) - P1 | N=11 | Recruiting | Sponsor: Brian Henick, MD | Initiation date: Nov 2024 ➔ Mar 2025

Adverse events • Trial initiation date • Brain Cancer • Breast Cancer • Colon Cancer • Colorectal Cancer • Endocrine Cancer • Esophageal Cancer • Gastric Cancer • Genetic Disorders • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Kidney Cancer • Liver Cancer • Lung Cancer • Oncology • Oral Cancer • Pancreatic Cancer • Prostate Cancer • Rectal Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Testicular Cancer • Thyroid Gland Carcinoma

IL-17C and Pityriasis Rubra Pilaris: Successful Treatment of Erythroderma With Brodalumab. (PubMed, Int J Dermatol) - No abstract available

Journal • Alopecia • Dermatopathology • Immunology • IL17C

Emerging Manifestations of IL-17 Immunomodulation in the Gastrointestinal Tract. (PubMed, Hum Pathol) - "Biologics targeting IL-17 (ixekizumab, secukinumab, brodalumab, bimekizumab) have been approved to treat conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The requirement of IBD biologics to achieve and maintain clinical/histologic remission in our cohort suggests that this process is more than a self-limited drug reaction. Future studies of expanded cohorts are required to determine whether IL-17 inhibitors unmask IBD in predisposed individuals or cause de novo IBD."

Journal • Ankylosing Spondylitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Primary Immunodeficiency • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials. (PubMed, Autoimmun Rev) - "Secukinumab showed sustained hidradenitis Suppurativa Clinical Response (HiSCR) improvements, particularly in biologic-naïve patients with common adverse events (AEs). Bimekizumab was effective with biweekly dosing, while the four-week regimen had inconsistent results, with rare reports of AEs. Brodalumab and bermekimab provided rapid and sustained HiSCR responses with lesion reductions, which were well tolerated. Guselkumab and ustekinumab showed promising but statistically nonsignificant improvements with mild AEs. Risankizumab did not significantly improve HiSCR rates but showed Dermatology Life Quality Index (DLQI) benefits. Anakinra offered moderate efficacy with prolonged exacerbation-free periods but led to some treatment discontinuations. Spesolimab reduced inflammatory lesions and draining tunnels while maintaining a favorable safety profile. IL inhibitors, especially IL-17 inhibitors, have demonstrated efficacy in treating moderate-to-severe HS, while..."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • IL17A • IL23A

Genetic polymorphisms in psoriasis: investigating genetic variations for precise profiling of response to brodalumab in real-life clinical practice. (PubMed, Actas Dermosifiliogr) - "This study identified genetic variations associated with the ability to achieve an optimal response to brodalumab, providing potential insights into its efficacy profile for treating plaque psoriasis."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • HTR2A